Pharming Group N.V. (PHGUF)
- Previous Close
0.0000 - Open
0.8270 - Bid 0.8747 x 312700
- Ask 0.9500 x 306000
- Day's Range
0.8270 - 0.8270 - 52 Week Range
0.7500 - 1.2900 - Volume
1,000 - Avg. Volume
873 - Market Cap (intraday)
586.235M - Beta (5Y Monthly) 0.84
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date Oct 24, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
34.00
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
www.pharming.comRecent News: PHGUF
View MorePerformance Overview: PHGUF
Trailing total returns as of 10/21/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PHGUF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PHGUF
View MoreValuation Measures
Market Cap
598.38M
Enterprise Value
560.08M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.24
Price/Book (mrq)
2.53
Enterprise Value/Revenue
2.02
Enterprise Value/EBITDA
77.77
Financial Highlights
Profitability and Income Statement
Profit Margin
-4.80%
Return on Assets (ttm)
-1.73%
Return on Equity (ttm)
-6.33%
Revenue (ttm)
277.56M
Net Income Avi to Common (ttm)
-13.32M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
160.32M
Total Debt/Equity (mrq)
55.23%
Levered Free Cash Flow (ttm)
-292k
Research Analysis: PHGUF
View MoreCompany Insights: PHGUF
PHGUF does not have Company Insights